El Sayed, Mira published the artcileInsights into Dissolution and Solution Chemistry of Multidrug Formulations of Antihypertensive Drugs, COA of Formula: C18H19Cl2NO4, the main research area is antihypertensive dissolution solubility supersaturation formulation; amorphous; fixed dose combinations; multidrug formulations; solubility; supersaturation.
Using fixed dose combinations of drugs instead of administering drugs sep. can be beneficial for both patients and the health care system, but the current understanding of how multidrug formulations work at the mol. level is still in its infancy. Here, we explore dissolution, solubility, and supersaturation of various drug combinations in amorphous formulations. The effect of chem. structural similarity on combination behavior was investigated by using structurally related compounds of both drugs. The effect of polymer type on solution behavior was also evaluated using chem. diverse polymers. Indapamide (IPM) concentration decreased when combined with felodipine (FDN) or its analogs, which occurred even when the IPM solution was undersaturated The extent of solubility decrease of FDN was less than that of IPM from the dissolution of an equimolar formulation of the drugs. No significant solubility decrease was observed for FDN at low contents of IPM which was also observed for other dihydropyridines, whereas FDN decreases at high contents of IPM. This was explained by the complex nature of the colloidal precipitates of the combinations which impacts the chem. potential of the drugs in solution at different levels. The maximum achievable concentration of FDN and IPM during dissolution of the polyvinylpyrrolidone-based amorphous solid dispersion was higher than the value measured with the hydroxypropyl methylcellulose acetate succinate-based formulation. This emphasizes the significance of mol. properties and chem. diversity of drugs and polymers on solution chem. and solubility profiles. These findings may apply to drugs administered as a single dosage form or in sep. dosage forms and hence need to be well controlled to assure effective treatments and patient safety.
Molecular Pharmaceutics published new progress about Amorphous materials. 72509-76-3 belongs to class pyridine-derivatives, name is 3-Ethyl 5-methyl 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate, and the molecular formula is C18H19Cl2NO4, COA of Formula: C18H19Cl2NO4.